The presentation will be held by CEO
Date and time
Webcast link
https://tv.streamfabriken.com/pressconference-2020-08-13
To participate via telephone, please dial-in on the numbers below
SE: +46 856642707
US: +1 8335268381
After the presentation, a recording of the webcast will be available on the webcast link.
For further information, please contact
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Mobile: +46 (0) 709 16 89 55
Certified Adviser
E-mail: info@fnca.se
Phone: +46 (0)8 528 003 99
The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CEST on
About Solasia
Solasia is a specialty pharmaceutical company based in
About the AGENT study
The Phase 3 AGENT study is a randomized, controlled, multi-centre study assessing the efficacy and safety of arfolitixorin, [6R]-5,10-methylene-THF acid (MTHF), compared to leucovorin, both used in combination with 5- FU, oxaliplatin, and bevacizumab, in first line metastatic colorectal cancer patients. Patients are randomized in a 1:1 ratio and the primary endpoint is overall response rate (ORR). The key secondary endpoints are progression free survival (PFS) and duration of response (DOR). Other secondary endpoints include overall survival (OS), number of curative metastasis resections, safety, and patient reported outcomes such as quality of life (QoL). Exploratory endpoints include pharmacokinetic (PK) measurements and level of gene expression of folate relevant genes in tumour cells. The study is designed to show superiority for arfolitixorin over leucovorin. The study is ongoing at approximately 90 sites in the
About arfolitixorin
Arfolitixorin is Isofol's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
About
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/invitation-to-a-conference-call-and-webcast-by-isofol-in-connection-with-the-entered-license-agreeme,c3167711
https://mb.cision.com/Main/15598/3167711/1290514.pdf
(c) 2020 Cision. All rights reserved., source